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developed world corporations (Janzen, 1991, p. 169 (Joyce, 1994 (Sittenfeld & Villers, 1995) . These are thought to comprise 5% to 7% of the world's total species (Merck & Co., 1991 (INBio, 1994) . INBio contributed 10% of the U.S. $1 million earned from the Merck-INBio agreement to the Island of Coco National Park (Sittenfeld, 1994 (Janzen, Hallwachs, Jimenez, & Gamez, 1993 (Caporale, 1992 (INBio, 1991; Merck, 1993) . Although it appears to be a small sum, U.S. $1 million is nearly ten times the traditional amount paid for biological samples (Reid, 1993 (Reid, -1994 .
Royalties from future drugs could be significant. Although the royalty rate is confidential, typical rates range from 1% to 15% (Watson, 1994 ). INBio's director, Rodrigo Gamez, put the royalty potential into perspective when he stated that a 2% or 3% royalty on 10 commercially marketed products would generate more income than do bananas and coffee together (Coughlin, 1993) . This optimism assumes that 10 products could be developed from Costa Rican samples to generate approximately U.S. $600,000,000 in royalties. Earning this much in royalties is overly optimistic given the fact that between 10,000 and 35,000 plant or animal samples must be assessed to yield one clinically useful drug (Reid, 1993 (Reid, -1994 A Model Agreement?
The reasons for building a Costa Rican connection were given by Lynn Caporale and Robert Bisset (Caporale, 1992) , Merck (Caporale, 1992; Merck & Co., 1991 (Reid et al., 1993 
